

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-6. (Cancelled)

7. (Currently amended) A method of reducing a bacterial population [:] in a subject in need of [[said]] treatment, said method comprising administering a therapeutically effective amount of a composition comprising an isolated phage tail that inhibits growth of a target bacterium, thereby reducing the growth of the bacterial population.

8. (Currently amended) The method of Claim 7, wherein [:]  
said subject is a human;  
~~said subject is a primate, a food, work, display, or a companion animal;~~  
~~said target bacterium is Escherichia, Staphylococcus, Pseudomonas, or Streptococcus;~~  
~~said method further comprises administering a second therapeutic or antimicrobial agent, including administering systemically, parenterally, orally, topically, or by inhalation, catheter, or drain tube;~~  
~~said method results in a relative decrease in said population of at least 10-1000 fold; or~~  
~~said method results in a decrease in detectability of said population by at least 5-50 fold.~~

9-10. (Cancelled).

11. (Previously presented) A method of treating a bacterial infection in a subject in need of such treatment, said method comprising a step of administering a therapeutically effective amount of a pharmaceutical composition comprising an isolated phage tail, wherein said isolated phage tail inhibits growth of a target bacterium, thereby treating the bacterial infection.

12. (Currently amended) The method of Claim 11, wherein [:]

said subject is a human;  
    said subject is a primate, a food, work, display, or companion animal;  
    said pharmaceutical composition is administered systemically, parenterally, orally,  
    topically, or by inhalation, catheter, or drain tube; or  
    said pharmaceutical composition is administered in combination with a second  
    therapeutic or anti-bacterial agent, e.g., an anti-microbial, inflammatory, or anti-inflammatory  
    agent.

13-21. (Canceled).

22. (Currently amended) A method of treating a bacterial colonization in a subject  
eukaryote experiencing colonization by a target bacterium, said method comprising  
administering to said subject eukaryote a defined dose therapeutic anti-bacterial composition  
comprising an isolated phage tail, thereby treating said bacterial colonization.

23. (Currently amended) The method of Claim 22, wherein [[:]]  
    said eukaryote is a mammal, including a primate;  
    said eukaryote said subject is a food, work, display, or companion animal;  
    said target bacterium is a pathogenic, nosocomial, or pyogenic bacterium;  
    said target bacterium is an Escherichia, Staphylococcus, Pseudomonas, or Streptococcus  
    bacterium;  
    said composition is administered systemically, parenterally, orally, topically, or by  
    inhalation, catheter, or drain tube;  
    said colonization has already been treated with an anti-microbial or antibiotic;  
    said colonization has been diagnosed to be susceptible to the selected composition; or  
    said eukaryote is also inoculated with another bacterium to replace said target bacterium.

24-25. (Canceled).

26. (New) The method of Claim 7, wherein said subject is a food, work, display, or a  
companion animal.

27. (New) The method of Claim 7, wherein said target bacterium is Escherichia, Staphylococcus, Pseudomonas, or Streptococcus.
28. (New) The method of Claim 7, wherein said method further comprises administering a second therapeutic or antimicrobial agent.
29. (New) The method of Claim 7, wherein said method results in a relative decrease in said population of at least 10-1000 fold.
30. (New) The method of Claim 7, wherein said method results in a decrease in detectability of said population by at least 5-50 fold.
31. (New) The method of Claim 11, wherein said subject is a primate, a food, work, display, or companion animal.
32. (New) The method of Claim 11, wherein said pharmaceutical composition is administered parenterally, orally, topically, by inhalation, catheter, or drain tube.
33. (New) The method of Claim 11, wherein said pharmaceutical composition is administered in combination with a second therapeutic selected from an anti-microbial, and an anti-inflammatory agent.
34. (New) The method of Claim 22, wherein said subject is a human.
35. (New) The method of Claim 22, wherein said target bacterium is a pathogenic, nosocomial, or pyogenic bacterium.
36. (New) The method of Claim 22, wherein said target bacterium is an Escherichia, Staphylococcus, Pseudomonas, or Streptococcus bacterium.
37. (New) The method of Claim 22, wherein said colonization has already been treated with an anti-microbial or antibiotic.

38. (New) The method of Claim 22, wherein said composition is administered parenterally, orally, topically, by inhalation, catheter, or drain tube.

39. (New) The method of Claim 22, wherein said target bacterium has been diagnosed to be susceptible to said composition.